Journal of Applied Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

J Appl Physiol (January 13, 2005). doi:10.1152/japplphysiol.00589.2004
This Article
Right arrow Full Text (PDF) Free
Right arrow All Versions of this Article:
98/5/1626    most recent
00589.2004v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tissot van Patot, M. C.
Right arrow Articles by Hackett, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tissot van Patot, M. C.
Right arrow Articles by Hackett, P.
Submitted on June 10, 2004
Accepted on January 12, 2005

Greater free plasma VEGF and lower soluble VEGF receptor-1 in Acute Mountain Sickness

Martha C. Tissot van Patot1*, Guy Leadbetter2, Linda E. Keyes3, Jamie Bendrick-Peart4, Virginia E. Beckey4, Uwe Christians1, and Peter Hackett3

1 Separtment of Anesthesiology, University of Colorado Health Sciences Center, Denver, CO, USA; Colorado Center for Altitude Medicine and Physiology, University of Colorado Health Sciences Center, Denver, CO, USA
2 Exercise Physiology, Mesa State College, Grand Junction, CO, USA; Colorado Center for Altitude Medicine and Physiology, University of Colorado Health Sciences Center, Denver, CO, USA
3 Colorado Center for Altitude Medicine and Physiology, University of Colorado Health Sciences Center, Denver, CO, USA
4 Separtment of Anesthesiology, University of Colorado Health Sciences Center, Denver, CO, USA

* To whom correspondence should be addressed. E-mail: martha.tissotvanpatot{at}uchsc.edu.

Vascular endothelial growth factor (VEGF) is a hypoxia-induced protein that produces vascular permeability, and limited evidence suggests a possible role for VEGF in the pathophysiology of acute mountain sickness (AMS), and/or high altitude cerebral edema (HACE). Previous studies demonstrated that plasma VEGF alone does not correlate with AMS; however, soluble VEGF receptor (sFlt-1), not accounted for in previous studies, can bind VEGF in the circulation, reducing VEGF activity. In the current study, we hypothesized that free VEGF is greater and sFlt-1 less in subjects with AMS as compared to well individuals at high altitude. Methods: Subjects were exposed to 4300 m for 19-20 hours (baseline 1600 m). The incidence of AMS was determined using a modified Lake Louise symptom score and the Environmental Symptoms Questionnaire for cerebral effects. Plasma was collected at low altitude and after 24 hours at high altitude, or at time of illness, and then analyzed by ELISA for VEGF and for soluble VEGF receptor, sFlt-1. Results: AMS subjects had lower sFlt-1 at both low and high altitude as compared to well subjects, and a significant rise in free plasma VEGF on ascent to altitude compared to well subjects. Conclusion: We conclude that increased free plasma VEGF on ascent to altitude is associated with AMS, and may play a role in pathophysiology of AMS.




This article has been cited by other articles:


Home page
 ChestHome page
R. B. Schoene
Illnesses at High Altitude
Chest, August 1, 2008; 134(2): 402 - 416.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
K. Kosaka, H. Fujiwara, S. Yoshioka, and S. Fujii
Vascular endothelial growth factor production by circulating immune cells is elevated in ovarian hyperstimulation syndrome
Hum. Reprod., June 1, 2007; 22(6): 1647 - 1651.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 1948 by the American Physiological Society.